NovaBay Pharmaceuticals, Inc. (AMEX:NBY) went down by -0.76% from its latest closing price when compared to the 1-year high value of $4.04 and move down -353.93%, while NBY stocks collected +3.42% of gains with the last five trading sessions. Press Release reported on 05/14/20 that Thinking about buying stock in Aurora Cannabis, Co-Diagnostics, NovaBay Pharmaceuticals, Aytu Bioscience, or American Airlines Group?

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Worth an Investment?

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) The 36 Months beta value for NBY stocks is at 3.88, while of the analysts out of 0 who provided ratings for NovaBay Pharmaceuticals, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $2.25 which is -$0.89 below current price. NBY currently has a short float of 2.22% and public float of 16.98M with average trading volume of 4.54M shares.

NBY Market Performance

NBY stocks went up by 3.42% for the week, with the monthly drop of -12.95% and a quarterly performance of 99.71%, while its annual performance rate touched -71.36%. The simple moving average for the period of the last 20 days is 0.22% for NBY stocks with the simple moving average of 33.13% for the last 200 days.

Analysts’ Opinion on NovaBay Pharmaceuticals, Inc. (AMEX:NBY)

Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY shares by setting it to “Buy”. The predicted price for NBY socks in the upcoming period according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY stock at the price of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 6, 2018.

Laidlaw gave “Buy” rating to NBY stocks, setting the target price at $8 in the report published on November 15, 2017.

NBY Stocks 0.63% Far from 50 Day Moving Average

After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, NovaBay Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -78.02% of loss for the given period.

The stock volatility was left at 6.30%, however, within the period of a single month, the volatility rate increased by 6.89%, while the shares sank at the distance of -12.09% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +16.83% upper at the present time.

In the course of the last 5 trading sessions, NBY went up by +3.42%, which changed the moving average for the period of 200 days to the total of +34.53% of gains for the stock in comparison to the 20-day moving average settled at $0.8798. In addition, NovaBay Pharmaceuticals, Inc. saw 38.73% in overturn over the period of a single year with a tendency to cut further gains.

NBY Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at NovaBay Pharmaceuticals, Inc. (NBY), starting from Fu Jian Ping, who sold 380,954 shares at the price of $3.84 back on Jun 11. After this action, Rushing now owns 5,302,350 shares of NovaBay Pharmaceuticals, Inc., valued at $1,462,863 with the latest closing price.

Pioneer Pharma (Hong Kong) Co , the 10% Owner of NovaBay Pharmaceuticals, Inc., sold 24,326 shares at the value of $4.04 during a trade that took place back on Jun 11, which means that Pioneer Pharma (Hong Kong) Co is holding 5,188,421 shares at the value of $98,277 based on the most recent closing price.

NBY Stock Fundamentals

The current profitability levels are settled at -140.02 for the present operating margin and +73.66 for gross margin. The net margin for NovaBay Pharmaceuticals, Inc. stands at -146.79. Total capital return value is set at -185.30, while invested capital returns managed to touch -301.21. Equity return holds the value -604.30%, with -69.80% for asset returns.

Based on NovaBay Pharmaceuticals, Inc. (NBY), the company’s capital structure generated 415.83 points for debt to equity in total, while total debt to capital is set at the value of 80.61. Total debt to assets is settled at the value of 36.06 with long-term debt to equity ratio rests at -8.77 and long-term debt to capital is 51.90.

The value for Enterprise to Sales is 3.14 with debt to enterprise value settled at 0.37. The receivables turnover for NovaBay Pharmaceuticals, Inc. is 2.89 with the total asset turnover at the value of 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.